Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma

References

• World Health Organization – WHO. International Agency for Research on Cancer. GLOBOCAN 2020: Cancer Today – Estimated number of new cases in 2020, worldwide, female, all ages; 2020. [cited 2021 Jan 1]. Available from: https://gco.iarc.fr/today/
   Google Scholar
• Brazil. Ministry of Health. National Cancer Institute José Alencar Gomes da Silva (INCA). Estimates 2020: Cancer Incidence in Brazil, Rio de Janeiro, 122. p. 2019. [cited 2021 Jan 1]. Available from: https://www.inca.gov.br/
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD. 2020. [cited 2021 Jan 1]. Available from: https://seer.cancer.gov/csr/1975_2017//
   Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines insights: ovarian cancer, version 1.2019. J Natl Compr Cancer Netw. 2019;17(8):896–909.
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338.
   PubMed Web of Science ®Google Scholar
• Takaya H, Nakai H, Murakami K, et al. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. Int J Clin Oncol. 2018;23(4):698–706.
   PubMed Web of Science ®Google Scholar
• Chen RC, Royce TJ, Extermann M, et al. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22(4):265–271.
   PubMed Web of Science ®Google Scholar
• Gérard S, Bréchemier D, Lefort A, et al. Body composition and anti-neoplastic treatment in adult and older subjects – a systematic review. J Nutr Health Aging. 2016;20(8):878–888.
   PubMed Web of Science ®Google Scholar
• Liutkauskiene S, Janciauskiene R, Jureniene K, et al. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer. 2015;15:105.
   PubMed Web of Science ®Google Scholar
• Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018;29(suppl_2):ii1–ii9.
   Web of Science ®Google Scholar
• Purcell SA, Elliott SA, Kroenke CH, et al. Impact of body weight and body composition on ovarian cancer prognosis. Curr Oncol Rep. 2016;18(2):8.
   PubMed Web of Science ®Google Scholar
• Daly LE, Power DG, O'Reilly Á, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116(3):310–317.
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Prado CM, Meyerhardt J, et al. Muscle radiodensity and mortality in patients with colorectal cancer. Cancer. 2018;124(14):3008–3015.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Deal AM, Weinberg M, et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for earlystage breast cancer. Clin Cancer Res. 2017;23(14):3537–3543.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving Taxane-Based chemotherapy. Clin Cancer Res. 2017;23(3):658–665.
   PubMed Web of Science ®Google Scholar
• Cousin S, Hollebecque A, Koscielny S, et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest New Drugs. 2014;32(2):382–387.
   PubMed Web of Science ®Google Scholar
• Sjøblom B, Grønberg BH, Benth JŠ, et al. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015;90(1):85–91.
   PubMed Web of Science ®Google Scholar
• Srdic D, Plestina S, Sverko-Peternac A, et al. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer. 2016;24(11):4495–4502.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Takano M, Miyamoto M, et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol. 2017;80(3):555–561.
   PubMed Web of Science ®Google Scholar
• Bertholee D, Maring JG, Van Kuilenburg ABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56(4):317–337.
   PubMed Web of Science ®Google Scholar
• Grabowski JP, Richter R, Rittmeister H, et al. Impact of body mass index (BMI) on chemotherapy-associated toxicity in ovarian cancer patients. A pooled analysis of the North-Eastern german society of gynecological oncology (NOGGO) Databank on 1,213 patients. Anticancer Res. 2018;38(10):5853–5858.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, Xiao J, et al. The association between body composition and toxicities from the combination of doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39(6):693–698.
   PubMed Web of Science ®Google Scholar
• Laky B, Janda M, Cleghorn G, et al. Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr. 2008;87(6):1678–1685.
   PubMed Web of Science ®Google Scholar
• Benedet JL, Bender H, 3rd JH, et al. FIGO committee on gynecologic oncology. FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancers. Int J Gynecol Obstet. 2000;70:209–262.
   PubMed Web of Science ®Google Scholar
• Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 2006;95:S161–S92.
   PubMed Web of Science ®Google Scholar
• Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol& Obstetr. 2014;124(1):1–5.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Brazil Ministry of Health. Clinical oncology service: Internal routines of INCA. Brazilian institute of cancer. Rio De Janeiro, RJ. 2011;241–245.
   Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–1756.
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S Redefining dose-limiting toxicity. Clin Adv Hematol Oncol. 2015;13:87–89.
   PubMed Web of Science ®Google Scholar
• Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr. 2016;35(3):724–730.
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034–1041.
   PubMed Web of Science ®Google Scholar
• Kazemi-Bajestani SMR, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016;54:2–10.
   PubMed Web of Science ®Google Scholar
• Tan BHL, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333–338.
   PubMed Web of Science ®Google Scholar
• Kok DE, Winkels RM, van Herpen CM, et al. Toxicity-induced modification of treatment: what is in a name? Eur. J.Cancer. 2018;104:145–150.
   PubMed Web of Science ®Google Scholar
• Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• National Cancer Institute – NIH. U.S. department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) – Version 5.0; 2017.
   Google Scholar
• Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J Clin Oncol. 1994;12(9):1748–1753.
   PubMed Web of Science ®Google Scholar
• World Health Organization – WHO. Guidelines for ATC classification and DDD assignment. ATC/DDD Index, 2021. [cited 2021 Jun 7]. Available from: https://www.whocc.no/atc_ddd_index//
   Google Scholar
• UpToDate database. [cited 2021. Jun 7]. Available from: https://www.uptodate.com/contents/search
   Google Scholar
• Drugs.com. Drug Interaction Checker; c1996-2018; 2020. [cited 2020 Dec 1]. Available from: https://www.drugs.com/drug_interactions.html
   Google Scholar
• Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115–122.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.
   PubMed Web of Science ®Google Scholar
• Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014;210(3):489–497.
   PubMed Web of Science ®Google Scholar
• Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 2010;13(3):260–264.
   PubMed Web of Science ®Google Scholar
• Gajra A, Klepin HD, Feng T, et al. Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. J Geriatr Oncol. 2015;6(2):133–140.
   PubMed Web of Science ®Google Scholar
• Au-Yeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014;133(1):16–22.
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Gonzalez-de-la-Fuente GA, Nazco GJ, et al. Hematological toxicity of carboplatin for gynecological cancer according to body mass index. Eur J Clin Pharmacol. 2016;72(9):1083–1089.
   PubMed Web of Science ®Google Scholar
• Nagel CI, Backes FJ, Hade EM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012;124(2):221–224.
   PubMed Web of Science ®Google Scholar
• Lhommé C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833). combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008;26(16):2674–2682.
   PubMed Web of Science ®Google Scholar
• Du bois A. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as First-Line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329.
   PubMed Web of Science ®Google Scholar
• Bronger H, Hederich P, Hapfelmeier A, et al. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer. 2017;27(2):223–232.
   PubMed Web of Science ®Google Scholar
• De Paula NS, Rodrigues CS, Chaves GV. Comparison of the prognostic value of different skeletal muscle radiodensity parameters in endometrial cancer. Eur J Clin Nutr. 2019;73(4):524–530.
   PubMed Web of Science ®Google Scholar
• Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016;142(2):311–316.
   PubMed Web of Science ®Google Scholar
• Rutten IJ, van Dijk DP, Kruitwagen RF, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients: Loss of skeletal muscle in ovarian cancer. J Cachexia Sarcopenia Muscle. 2016;7(4):458–466.
   PubMed Web of Science ®Google Scholar
• Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107–2118.
   PubMed Web of Science ®Google Scholar
• Hilmi M, Jouinot A, Burns R, et al. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135–159.
   PubMed Web of Science ®Google Scholar
• Kurk S, Peeters P, Stellato R, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019;10(4):803–813.
   PubMed Web of Science ®Google Scholar
• Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer: psoas muscle for assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):630–638.
   PubMed Web of Science ®Google Scholar
• Staley A, Tucker K, Newton M, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020;156(3):695–700.
   PubMed Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies: prognostic role of muscle density. Cancer. 2013;119(18):3377–3384.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547.
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Kelley DE, Thaete FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000;89(1):104–110.
   PubMed Web of Science ®Google Scholar
• Bhullar AS, Anoveros-Barrera A, Dunichand-Hoedl A, et al. Lipid is heterogeneously distributed in muscle and associates with low radiodensity in cancer patients. J. Cachexia Sarcopenia Muscle. 2020;11(3):735–747.
   PubMed Web of Science ®Google Scholar
• Rollins KE, Tewari N, Ackner A, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35(5):1103–1109.
   PubMed Web of Science ®Google Scholar
• Daly LE, Ní Bhuachalla ÉB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer: Muscle loss during chemotherapy is prognostic of poor survival. J Cachexia Sarcopenia Muscle. 2018;9(2):315–325.
   PubMed Web of Science ®Google Scholar
• Dijksterhuis WPM, Pruijt MJ, van der Woude SO, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019;10(1):199–206.
   PubMed Web of Science ®Google Scholar
• Aleixo GFP, Shachar SS, Nyrop KA, et al. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;145:102839.
   PubMed Web of Science ®Google Scholar
• Da Rocha IMG, Marcadenti A, Medeiros GOC, et al. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle. 2019;10(2):445–454.
   PubMed Web of Science ®Google Scholar
• McSharry V, Mullee A, McCann L, et al. The impact of sarcopenia and low muscle attenuation on overall survival in epithelial ovarian cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2020;27(9):3553–3356.
   PubMed Web of Science ®Google Scholar
• Rier HN, Jager A, Sleijfer S, et al. Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2018;168(1):95–105.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Krzyzanowska MK. Drug interactions and oncological outcomes: a hidden adversary. Ecancermedicalscience. 2019;13:ed88.
   PubMed Web of Science ®Google Scholar
• Buchner P, Buchler W, Wagenbauer E, et al. Dose reduction and delay or discontinuation of chemotherapy in cancer patients experiencing potential drug-drug interactions. Eur J Hosp Pharm. 2016;23(Suppl 1):A29.1–A29.
   Google Scholar
• Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437–2448.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLOS One. 2012;7(5):e37563.
   PubMed Web of Science ®Google Scholar